Severe hepatic necrosis of unknown causes following ABO-incompatible liver transplantation

Hao Lu, Chuan-Yong Zhang, Wei Ding, Yun-Jie Lu, Guo-Qiang Li, Feng Zhang, Ling Lu

Abstract
Emergency ABO-incompatible (ABO-I) liver transplantations (LTx) have been performed increasingly to treat severe liver failure. Herein, we report a case of severe hepatic necrosis after ABO-I LTx. A 53-year-old man with blood group O was diagnosed as having severe hepatitis B and acute-on-chronic liver failure, and underwent an emergency liver transplantation implanting a blood-group-B liver from a cardiac-death donor. A routine anti-rejection, anti-infection and anti-virus therapy was given after operation. On post-operative day (POD) 16, the recipient had fever and erythra. Laboratory and radiographic examinations suggested a severe hepatic necrosis of unknown causes. The patient was managed with a 10-d methylprednisolone pulse therapy. He was discharged on POD 35 with stable condition, and no recurrent disease was found during the follow-up.

© 2013 Baishideng. All rights reserved.

Key words: Liver transplantations; ABO-incompatible; Hepatic necrosis; Graft rejection; Pulse therapy
the patient was cured and discharged.

CASE REPORT

A 53-year-old male patient was transferred from the internal medical ward to the liver transplant unit after he was diagnosed as having severe hepatitis B and ACLF, and he then underwent an emergency ABO-I LTx. The liver graft was obtained from a cardiac-death donor with blood group B, which mismatched the recipient’s blood group O. Cold ischemia time of the graft was 5 h. The modified piggy orthotopic liver transplantation was performed with a 60-min anhepatic phase and without splenectomy. Massive ascites (about 4000 mL), omentum and gallbladder edema, enlarged tough spleen and severe atrophic and cirrhotic liver were visualized after a right upper incision, confirming the diagnosis of ACLF. The operation was successful. Basiliximab 20 mg and methylprednisolone 1000 mg were administered for immune-induction and hepatitis B immunoglobulin (HB-Ig) 1000 U for prevention of hepatitis B virus (HBV) recurrence before anhepatic phase. A quadruple therapy was given to prevent rejection: (1) Ritusimab 100 mg on post-operative day (POD) 1 and Basiliximab 20 mg on POD 4 for induction of immune tolerance; (2) Tacrolimus (Tac) at a dose adjusted according to a blood level of 10-15 ng/mL; (3) Methylprednisolone (MP) at a dose gradually reduced from 1000 mg qd to a maintenance of 10 mg bid; and (4) Mycophenolate mofetil, 0.5 g, bid. Other treatments included administration of antibiotics, antiviral therapy with lamivudine, proton pump inhibitor and liver-protective medication. Primary monitoring examinations included blood routine, liver function, coagulation function, HBV serum virology, serum drug level of Tac, B-ultrasound (B-US) and computed tomography (CT) scan. Pathological examination, lymphocyte subsets analysis and ImmuKnow Assay (T cell function test) results showed no rejection. On POD 16, the patient had fever and erythra. B-US displayed a sub-hepatic, pelvic and thoracic fluid sonolucent area, while CT scan showed abnormal left liver lobe infuision and slight intrahepatic bile duct dilatation (Figure 1). Both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were elevated (ALT 54.3 U/L and AST 26.5 U/L vs ALT 1204.2 U/L and AST 1555.3 U/L at POD 12 and 16, respectively). All these results indicated a severe hepatic necrosis. After a 10-d MP pulse therapy, the patient's symptoms were relieved and amnitoransferase was reduced. The patient was discharged on POD 35, and was followed up once a month. The patient is doing well without any recurrent disease.

DISCUSSION

The initial clinical impression of severe hepatic necrosis on POD 16 was rejection. AMR is triggered by alloantibody binding and compliment activation. In the case of ABO-I solid organ transplantation, A, B or AB blood group antigens expressed on graft could be detected by specific natural antibodies. Incompatible blood group antigens activated B cells directly with the help of T cells and resulted in transcription of cytokines and antibodies[11]. AMR can be caused by performed antibodies, anamnestic B-cell responses, early de novo and late de novo B-cell responses. The strength of isohemagglutinins and natural antibodies in ABO-I recipients can be detected and quantified by multiple methods. Antibody titer is reported to correlate with the survival of recipients. ABO-I living donor liver transplantation with high preoperative and postoperative immunoglobulin (Ig) G and IgM levels sustained bile duct complication and hepatic necrosis, respectively[12], while the safe value of isohemagglutinin titer is ≤ 1:16 for kidney transplantation[13,14] and ≤ 1:4 for pediatric heart transplantation[15,16]. In this case, on POD 16, the recipient run a fever, and had poor liver function, and CT scan showed intrahepatic bile duct dilatation and liver necrosis in the left lobe (Figure 1A). But lymphocyte subset analysis indicated a slight increase of T cells and a drop of B cells (CD3+ 77.9%, CD3+CD4+ 49.7%, CD3+CD8+ 23.9%, CD3-CD16+CD56 14.4% and CD19+ 1%), which was contradictory to AMR with an enhanced B cell function. Meanwhile, ImmuKnow Assay (T cell function tests) before LTx and on POD 34 and
Lu H et al. Severe hepatic necrosis after ABO-I LTx

Figure 2  Blood routine test results after ABO-incompatible liver transplantation. Due to treatment with tacrolimus and methylprednisolone, the number of lymphocyte stayed stable before and after the occurrence of severe hepatic necrosis, while the total number of white blood cell counts was mainly affected by neutrophil changes, which might be induced by non-specific reasons, e.g., phagocytosis and absorption of necrotic tissues. LTx: Liver transplantation; POD: Post-operative day; HN: Hepatic necrosis; WBC: White blood cell; L: Lymphocyte; N: Neutrophil.

90 were 156.7 ng/mL, 101.7 ng/mL and 70.3 ng/mL, respectively, suggesting a depression of T cell function after LTx resulting from immunosuppressive therapy[15,16]. The total number of white blood cell was mainly affected by neutrophils (Figure 2). Levels of IgG, IgA, IgM, C3 and C4 were normal or almost normal before LTx and on POD 118 (18.1 g/L, 3.45 g/L, 0.94 g/L, 0.20 g/L and 0.0159 g/L vs 7.1 g/L, 1.38 g/L, 0.51 g/L, 1.07 g/L and 0.305 g/L, respectively). Therefore, rejection was not considered as the cause of hepatic necrosis initially.

Another factor leading to severe hepatic necrosis after LTx was recurrent diseases. To prevent recurrent hepatitis B, HB-Ig and/or lamivudine was administered. A 10-year follow-up study in 24 individuals with chronic hepatitis B demonstrated the effectiveness of HB-Ig and/or lamivudine[17]. Nineteen patients were alive after the follow-up duration with well-functioning graft. None of them developed recurrent hepatitis B. Among them, 12 patients received HB-Ig and lamivudine, 3 received lamivudine only, 1 received adefovir, and 3 received no antivirals. HBsAg and HbcAb were both positive in the serum virology test in this patient before LTx. Antiviral treatments included HB-Ig 1000 U injection during LTx and lamivudine p.o. after operation. Post-LTx HBV examination results were all negative. Pathological examination of the explanted liver showed classic necrotic changes, without hepatocellular carcinoma. Taken together, there was no recurrent hepatitis or carcinoma till the last follow-up in this case, although CT scan showed dilatation of bile duct and inflammation of left liver lobe (Figure 1A), which could result from recurrent viral hepatitis[18].

Blood supply disorders and biliary complications could also lead to hepatic necrosis after LTx. CT scan and CT angiography (CTA) also suggested normal hemodynamics on POD 3, but a low-density cystic echo (6.1 cm x 13 cm) and a filling defect (2.1 cm x 1.9 cm) at the portal area (Figure 1B). However, as shown in Figure 3A, total bilirubin and creatinine levels turned normal on POD 7 according to Li et al.[19], and remained stable during hepatic necrosis after LTx. Besides, ALT and AST levels started to fall on POD 20, i.e., 4 d after an MP pulse therapy for severe hepatic necrosis, indicating that liver function had been improved (Figure 3B). As demonstrated in Figure 3C, PT and INR became normal on POD 5[20], and B-US on POD 16 showed no sign of intrahepatic thrombosis and stricture. To prevent postoperative bleeding, hemocoagulase was injected which would not result in prothrombin increase and thrombosis. So we excluded vascular or biliary complications. Low molecular weight
heparin calcium injection was also given till POD 30 for 14 d. However, CT scan and CTA on POD 118 showed a smaller low-density cyst (5 cm × 10 cm) and a same-sized filling defect (2.1 cm × 1.9 cm) at portal area compared with the earlier findings (Figure 1C), which indicated no deterioration of blood supply.

In conclusion, coagulatory, immunologic and hepatic functions after LTx were complicated, and we have not encountered such case before at our center. This patient had severe hepatic necrosis on POD 16, which might be attributed to the rejection with atypical manifestation due to immune suppressive therapy. However, the patient recovered in liver function after treatment with MP, and discharged on POD 34. Till the last follow-up 10 mo after LTx, there were no symptoms or signs indicating bad prognosis. Although the mechanism for hepatic necrosis and recovery of similar cases needs further studies, our experience has provided evidence that emergency ABO-I LTx is an effective treatment option for ACLF, and secondary liver necrosis of unknown causes might be treated by MP.

REFERENCES
1. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riodan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takayawa Y, Thapa BR, Wei CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3: 269-282 [PMID: 19669378 DOI: 10.1016/s1207-2258(09)-0160-x]
2. Katoonzadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59: 1561-1569 [PMID: 20675604 DOI: 10.1136/gut.2009.189639]
3. Rajekar H, Wei CT, Majeed TA, Lee KH, Wong SY, Leong SO, Singh R, Tay KH, Soosaynathan C, Tan KC. Prognostic factors in patients with acute liver failure undergoing live donor liver transplantation. Transplant Proc 2008; 40: 2492-2493 [PMID: 18929776 DOI: 10.1016/j.transproceed.2008.07.009]
4. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mützen S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-958 [PMID: 12297843 DOI: 10.1053/jhep.2002.36130]
5. Hassanein TI, Tofteng F, Brown RS, McGuire B, Lynch P, Mehta R, Larsen FS, Gorbein J, Stange J, Blei AT. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-1862 [PMID: 17957845 DOI: 10.1002/hep.21930]
6. Nevens F, Laleman W. Artificial liver support devices as treatment option for liver failure. Best Pract Res Clin Gastroenterol 2012; 26: 17-26 [PMID: 22482522 DOI: 10.1016/j.bpcg.2011.01.002]
7. Tritt G, Davies NA, Jalan R. Liver replacement therapy. Semin Respir Crit Care Med 2012; 33: 70-79 [PMID: 22447262 DOI: 10.1055/s-0032-1301736]
8. Nakamura Y, Hama K, Iwamoto H, Yokoyama T, Kihara Y, Konno O, Jojima Y, Shimazu M. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding米兰 criteria in a patient with hepatitis B virus cirrhosis: a case report. Transplant Proc 2012; 44: 565-569 [PMID: 22400700 DOI: 10.1016/j.transproceed.2012.01.029]
9. Yamada N, Urahashi T, Ibara Y, Sanada Y, Wakiya T, Okada N, Mizuta K. Veno-occlusive disease/sinusoidal obstruction syndrome associated with potential antibody-mediated rejection after pediatric living donor liver transplantation: a case report. Transplant Proc 2012; 44: 810-815 [PMID: 22483502 DOI: 10.1016/j.transproceed.2012.01.008]
10. Yamanouchi K, Eguchi S, Takatsuki M, Kamohara Y, Hi-daka M, Miyazaki K, Inokuma T, Tajima Y, Kanematsu T. Management of cytomegalovirus infection after living donor liver transplantation. Hepatogastroenterology 2012; 59: 231-234 [PMID: 22251542 DOI: 10.5754/hge09582]
11. Montgomery RA, Cozzi E, West LJ, Warren DS. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol 2011; 23: 224-234 [PMID: 21958660 DOI: 10.1016/j.smim.2011.08.021]
12. Kozaki K, Egawa H, Ueda M, Oke F, Yoshizawa A, Fukutsu A, Takada Y. The role of apheresis therapy for ABO incompatible living donor liver transplantation: the Kyoto University experience. Ther Apher Dial 2006; 10: 441-448 [PMID: 17096700 DOI: 10.1111/j.1744-9987.2006.00409.x]
13. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL, Stewart ZA, Melancon JK, Ratner L, Zachary AA, Haas M. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246-1255 [PMID: 19384174 DOI: 10.1097/TP.0b013e318192024]
14. Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, Shirley RS, Haas M, Leffell MS, Montgomery RA. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4: 561-568 [PMID: 15022348 DOI: 10.1111/j.1600-6143.2004.00364.x]
15. Irving C, Parry G, Cassidy J, Hasan A, Grissell M, Kirk R. Outcomes following infant listing for cardiac transplantation: the impact of strategies introduced to counteract limited donor availability. Arch Dis Child 2010; 95: 883-887 [PMID: 20656734 DOI: 10.1136/adc.2009.171548]
16. Roche SL, Burch M, O’Sullivan J, Wallis J, Parry G, Kirk R, Elliot M, Shaw N, Flett J, Hamilton JR, Hasan A. Multicenter experience of ABO-incompatible pediatric cardiac transplantation. Am J Transplant 2008; 8: 208-215 [PMID: 18021280 DOI: 10.1111/j.1600-6143.2007.02040.x]
17. Gralla J, Huskey J, Wiseman AC. Trends in immune function assay (ImmunoKnow, Cylex(®)) results in the first year post-transplant and relationships to BK virus viremia. Nephrol Dial Transplant 2012; 27: 2565-2570 [PMID: 22167591 DOI: 10.1093/ndt/gfr675]
18. Berglund D, Bengtsson M, Biglarnia A, Berglund E, Yamamoto S, von Zur-Mühlen B, Lorant T, Tufveson G. Screening of mortality in transplant patients using an assay for immune function. Transplant Int 2011; 24: 246-250 [PMID: 21232600 DOI: 10.1016/j.troim.2012.10.005]
19. Yataco M, Bonatti H, Machicavo C, Mendez J, Stauffer J, Nguyen J, Ghabril M, Aranda-Michel J, Dickson R. Long term survival and complications after liver transplantation in patients with chronic hepatitis B. Ann Transplant 2010; 15: 27-34 [PMID: 20657516]
20. Petrovic LM. Recurrent diseases following liver transplantation: current concepts. Curr Opin Organ Transplant 2012; 17: 293-302 [PMID: 22498649 DOI: 10.1097/MOT.0b013e3283356366]
21. Li C, Mi K, Wen Tl, Yan Ll, Bi B, Yang Jy, Xu Mq, Wang Wt, Wei Yg. Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantation. PLoS One 2011; 6: e27366 [PMID: 22087299 DOI: 10.1371/journal.pone.0027366]

P-Reviewer Ramsay M  S-Editor Gou SX  L-Editor A  E-Editor LJ